Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial

The Lancet Neurology

Volumn 15, Issue 11, 2016, Pages 1138-1147

  Bracard, Serge ^a   Ducrocq, Xavier ^a   Mas, Jean Louis ^b   Soudant, Marc ^a   Oppenheim, Catherine ^b   Moulin, Thierry ^c   Guillemin, Francis ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTERY PERFORATION; ARTICLE; BARTHEL INDEX; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL OUTCOME; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; GROIN HEMATOMA; HUMAN; INTENTION TO TREAT ANALYSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MECHANICAL THROMBECTOMY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANKIN SCALE; THROMBECTOMY; TREATMENT DURATION; TREATMENT OUTCOME; VASOSPASM; AGED; CLINICAL TRIAL; DIAGNOSTIC IMAGING; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STROKE;

AGED; BRAIN ISCHEMIA; COMBINED MODALITY THERAPY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MECHANICAL THROMBOLYSIS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84991014378     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)30177-6     Document Type: Article

References (25)

1. 1 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995), 1581–1587.
2. 2 Hacke, W, Kaste, M, Bluhmki, E, et al. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 359 (2008), 1317–1329.
3. 3 Wahlgren, N, Ahmed, N, Davalos, A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 (2007), 275–282.
4. 4 Emberson, J, Lees, KR, Lyden, P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 384 (2014), 1929–1935.
5. 5 Saqqur, M, Uchino, K, Demchuk, AM, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 38 (2007), 948–954.
6. 6 De Silva, DA, Brekenfeld, C, Ebinger, M, et al. The benefits of intravenous thrombolysis related to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). Stroke 41 (2010), 295–299.
7. 7 Broderick, JP, Palesch, YY, Demchuk, AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 368 (2013), 893–903.
8. 8 Ciccone, A, Valvassori, L, Nichelatti, M, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med 368 (2013), 904–913.
9. 9 Kidwell, CS, Jahan, R, Gornbein, J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 368 (2013), 914–923.
10. 10 Berkhemer, OA, Fransen, PSS, Beumer, D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 372 (2015), 11–20.
11. 11 Campbell, BCV, Mitchell, PJ, Kleinig, TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 372 (2015), 1009–1018.
12. 12 Goyal, M, Demchuk, AM, Menon, BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 372 (2015), 1019–1030.
13. 13 Saver, JL, Goyal, M, Bonafe, A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 372 (2015), 2285–2295.
14. 14 Jovin, TG, Chamorro, A, Cobo, E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 372 (2015), 2296–2306.
15. 15 Badhiwala, JF, Nassiri, F, Alhazzani, W, et al. Endovascular thrombectomy for acute ischemic stroke. A meta-analysis. JAMA 314 (2015), 1832–1843.
16. 16 Pocock, SJ, Simon, R, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31 (1975), 103–115.
17. 17 Barber, PA, Demchuk, AM, Zhang, J, Buchan, AM, Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet 355 (2000), 1670–1674.
18. 18 McTaggart, RA, Jovin, TG, Lansberg, MG, et al. Alberta Stroke Program Early Computed Tomographic Scoring performance in a series of patients undergoing computed tomography and MRI: reader agreement, modality agreement, and outcome prediction. Stroke 46 (2015), 407–412.
19. 19 Zaidat, OO, Yoo, AJ, Khatri, P, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke 44 (2013), 2650–2663.
20. 20 van Swieten, JC, Koudstaal, PJ, Visser, MC, Schouten, HJ, van Gijn, J, Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19 (1988), 604–607.
21. 21 Mahoney, FI, Barthel, DW, Functional evaluation: the Barthel Index. Md State Med J 14 (1965), 61–65.
22. 22 EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16 (1990), 199–208.
23. 23 Zou, G, A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159 (2004), 702–706.
24. 24 Fazekas, F, Chawluk, JB, Alavi, A, et al. MR signal abnormalities at 1·5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149 (1987), 351–356.
25. 25 Goyal, M, Menon, BK, van Zwam, WH, et al., for the HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 387 (2016), 1723–1731.